Effect of once-daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: A 26-week Asia-Pacific study

Respirology

Volumn 19, Issue 2, 2014, Pages 231-238

  Yao, Wanzhen ^a   Wang, Changzheng ^b   Zhong, Nanshan ^c   Han, Xiaowen ^d   Wu, Changgui ^e   Yan, Xixin ^f   Chen, Ping ^g   Yang, Wei ^h   Henley, Michelle ^h   Kramer, Benjamin ^h  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

^d HEBEI GENERAL HOSPITAL   (China)

^e HEBEI MEDICAL UNIVERSITY   (China)

^f FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^g CENTRAL SOUTH UNIVERSITY   (China)

^h NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Chinese; chronic obstructive pulmonary disease; efficacy; indacaterol; safety

Indexed keywords

INDACATEROL; PLACEBO; INDAN DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; AGED; ARTICLE; CHINESE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; EOSINOPHILIA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; OROPHARYNX PAIN; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VIRAL UPPER RESPIRATORY TRACT INFECTION; CHINA; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; FOLLOW UP; HEALTH STATUS; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRE; TIME FACTOR;

AGED; CHINA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMANS; INCIDENCE; INDANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84892586719     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12211     Document Type: Article

References (23)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2013. [Accessed 4 Mar 2013.] Available from URL: http://www.goldcopd.org
2. Lin HH, Murray M, Cohen T, Colijn C, Ezzati M,. Effects of smoking and solid-fuel use on COPD, lung cancer, and tuberculosis in China: a time-based, multiple risk factor, modelling study. Lancet 2008; 372: 1473-1483.
3. Zhong N, Wang C, Yao W, Chen P, Kang J, Huang S, Chen B, Wang C, Ni D, Zhou Y, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am. J. Respir. Crit. Care Med. 2007; 176: 753-760.
4. Cazzola M, Matera MG, Lotvall J,. Ultra long-acting beta 2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin. Investig. Drugs 2005; 14: 775-783.
5. Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B, INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010; 65: 473-479.
6. Donohue JF, Fogarty C, Lotvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, et al.; INHANCE Study Investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am. J. Respir. Crit. Care Med. 2010; 182: 155-162.
7. Feldman G, Siler T, Prasad N, Jack D, Piggott S, Owen R, Higgins M, Kramer B, INLIGHT 1 study group. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomized, 12-week study. BMC Pulm. Med. 2010; 10: 11. doi: 10.1186/1471-2466-10-11.
8. Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B, INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-μg Doses with COPD Patients) study investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur. Respir. J. 2011; 37: 273-279.
9. Kinoshita M, Lee SH, Hang LW, Ichinose M, Hosoe M, Okino N, Prasad N, Kramer B, Fukuchi Y, Indacaterol Asian COPD Study Investigators. Efficacy and safety of indacaterol 150 and 300 microg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study. Respirology 2012; 17: 379-389.
10. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2007. [Accessed 10 Nov 2011.] Available from URL: http://www.goldcopd.org
11. Mahler DA, Witek TJ Jr,. The MCID of the transition dyspnea index is a total score of one unit. COPD 2005; 2: 99-103.
12. Jones PW St,. George's Respiratory Questionnaire: MCID. COPD 2005; 2: 75-79.
13. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, et al.; American Thoracic Society; European Respiratory Society Task Force on Outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur. Respir. J. 2008; 31: 416-469.
14. Kato M, Makita H, Uemura K, Fukuchi Y, Hosoe M, Emery C, Higgins M, Kramer B,. Bronchodilator efficacy of single doses of indacaterol in Japanese patients with COPD: a randomized, double-blind, placebo-controlled trial. Allergol. Int. 2010; 59: 285-293.
15. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ,. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 1005-1012.
16. Cooper CB,. Airflow obstruction and exercise. Respir. Med. 2009; 103: 325-334.
17. Hanania NA, Donohue JF,. Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Proc. Am. Thorac. Soc. 2007; 4: 526-534.
18. Beeh KM, Wagner F, Khindri S, Drollmann AF,. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD 2011; 8: 340-345.
19. O'Donnell DE, Casaburi R, Vincken W, Puente-Maestu L, Swales J, Lawrence D, Kramer B, INABLE 1 Study Group. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir. Med. 2011; 105: 1030-1036.
20. Balint B, Watz H, Amos C, Owen R, Higgins M, Kramer B, INSURE Study Investigators. Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone. Int. J. Chron. Obstruct. Pulmon. Dis. 2010; 5: 311-318.
21. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775-789.
22. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543-1554.
23. Zhou YM, Wang XP, Zeng XY, Qiu R, Xie JF, Liu SM, Zheng JP, Zhong NS, Ran PX,. Theophylline in the treatment of chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled study. Zhonghua Jie He He Hu Xi Za Zhi 2006; 29: 577-582.